MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Founder and CEO Justin Hanka joined the latest episode of the TechMediaWire Podcast to discuss the company’s artificial intelligence-driven voice analysis technology designed to detect drug and alcohol intoxication through noninvasive speech analysis. During the interview, Hanka outlined the limitations of traditional testing methods and described MindBio’s commercial focus on regulated workplace environments such as mining, where the company believes its scalable detection platform could improve safety by expanding real-time intoxication screening capabilities.
MindBio is a biotechnology company that is commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.
The interview highlights the potential of MindBio's technology to transform workplace safety by providing a noninvasive, scalable alternative to traditional methods like breathalyzers and urine tests. In industries such as mining, where real-time detection is critical, the platform could enable continuous monitoring, reducing the risk of accidents caused by impaired workers. Hanka emphasized that the platform's AI model, trained on over 50 million data points, achieves high accuracy in predicting alcohol intoxication solely from voice samples, making it a powerful tool for employers.
For investors, the discussion underscores MindBio's strategic focus on high-risk industries with stringent safety regulations. The company's Edge-AI kiosks, which integrate hardware and software into a turnkey solution, are designed for easy deployment in enterprise settings. As regulatory scrutiny around workplace intoxication increases, MindBio's technology could address a growing demand for efficient, noninvasive screening methods.
The full podcast episode is available on the TechMediaWire platform. For more information about MindBio Therapeutics, visit the company’s newsroom at https://ibn.fm/MBQIF.
